scholarly journals Angiotensin-Converting Enzyme Inhibitor-associated Angioedema Treated with c1-esterase Inhibitor: A Case Report and Review of the Literature

2016 ◽  
Vol 7 (3) ◽  
pp. ar.2016.7.0166 ◽  
Author(s):  
Davis Lynn Erickson ◽  
Christopher Albert Coop

Case Report A 59-year old man currently on >5 years of angiotensin-converting enzyme inhibitor (ACEI) therapy presented to the emergency department with angioedema of the tongue and difficulty swallowing. After receiving conventional therapy of antihistamine, steroids, and epinephrine, the patient's condition continued to deteriorate, with imminent intubation. The patient was treated with a C1-esterase inhibitor (C1-INH) and experienced rapid resolution of symptoms, which avoided airway complications. Discussion Although no therapy has been approved for the treatment of ACEI–associated angioedema (AAE), the conventional therapy (antihistamine, steroids, and epinephrine) often proves ineffective in this bradykinin-mediated angioedema. There are drugs approved and used for hereditary angioedema that may be effective in the acute phase of ACEI-AAE that may prevent the need for further interventions, such as intubation and tracheotomy. These drugs include icatibant, ecallantide, fresh frozen plasma, and C1-INH. Conclusion The literature and clinical evidence indicate C1-INH can be effectively used in the treatment of ACEI-AAE to halt the progression of the condition, prevent airway compromise and the need for intervention, and lead to rapid resolution of symptoms.

2015 ◽  
Vol 125 (6) ◽  
pp. E198-E202 ◽  
Author(s):  
Jens Greve ◽  
Murat Bas ◽  
Thomas K. Hoffmann ◽  
Patrick J. Schuler ◽  
Patrick Weller ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Thorbjørn Hermanrud ◽  
Nicolaj Duus ◽  
Anette Bygum ◽  
Eva Rye Rasmussen

Angioedema of the upper airways is a severe and potentially life-threatening condition. The incidence has been increasing in the past two decades, primarily due to pharmaceuticals influencing the generation or degradation of the vasoactive molecule bradykinin. Plasma-derived C1-esterase inhibitor concentrate is a well-established treatment option of hereditary and acquired complement C1-esterase inhibitor deficiency, which are also mediated by an increased level of bradykinin resulting in recurrent angioedema. We here present a case of severe angiotensin converting enzyme-inhibitor related angioedema (ACEi-AE) of the hypopharynx that completely resolved rapidly after the infusion of plasma-derived C1-inhibitor concentrate adding to the sparse reports in the existing literature.


2016 ◽  
Vol 23 (3) ◽  
pp. 166-169 ◽  
Author(s):  
Beatriz Frutuoso ◽  
Joana Esteves ◽  
Mafalda Silva ◽  
Pedro Gil ◽  
Ana Cristina Carneiro ◽  
...  

2019 ◽  
Vol 69 (5) ◽  
pp. 521-526
Author(s):  
Flora Margarida Barra Bisinotto ◽  
Beatrice Cavalcanti Seabra ◽  
Fernando B. Prata Lóes ◽  
Laura Bisinotto Martins ◽  
Luciano Alves Matias da Silveira

Sign in / Sign up

Export Citation Format

Share Document